The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 155.00
Bid: 150.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 10.00 (6.667%)
Open: 155.00
High: 155.00
Low: 155.00
Prev. Close: 155.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Mar 2017 10:54

RNS Number : 7446Y
Faron Pharmaceuticals Oy
07 March 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Faron Pharmaceuticals Oy

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

 

Legal & General Group Plc (L&G)

 

Legal & General (Unit Trust Managers) Limited (UTM)

 

4. Full name of shareholder(s)  (if different from 3.):

 

N/A

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

03 March 2017

6. Date on which issuer notified:

07 March 2017

7. Threshold(s) that is/are crossed orreached:

 

UTM (Below 5%)

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD NPV

1,365,000.00

 Below 5%

-

 Below 5%

-

 Below 5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 

 UTM

(Below 5%)

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 1,565,000 - 5.64%= Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 1,565,000 - 5.64%= Total Position)

Legal & General (Unit Trust Managers) Limited (Below 5% = UTM)

Legal & General Group Plc (Direct) (L&G) ( Below 3% = LGAS, & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH) (LGAS)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

 

 

 

 

13. Additional information:

Notification using the total voting rights figure of  27,734,044

14. Contact name:

Victoria Davies (LGIM)

15. Contact telephone number:

029 2035 4147

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLKMGGFGNMGNZM
Date   Source Headline
5th Mar 201810:12 amRNSHolding(s) in Company
2nd Mar 20181:30 pmRNSHolding(s) in Company
2nd Mar 20181:25 pmRNSHolding(s) in Company
1st Mar 201812:42 pmRNSHoldings in Company
1st Mar 201812:41 pmRNSHoldings in Company
26th Feb 20181:37 pmRNSIssue of Equity
21st Feb 20183:31 pmRNSResults of Placing & Issue of Equity
21st Feb 20187:00 amRNSFaron hosts R&D Day today in London
16th Feb 20187:00 amRNSProposed Placing to raise up to £15m
5th Feb 20187:00 amRNSSecond Traumakine manufacturing site established
1st Feb 20187:00 amRNSFaron Announces Clevegen Grant of European Patent
29th Jan 20187:00 amRNSFDA grants Fast Track Designation for Traumakine®
24th Jan 20187:00 amRNSFDA approval of Faron's Traumakine® IND
19th Dec 20177:00 amRNSINFORAAA trial receives recommendation from IDMC
14th Dec 20177:00 amRNSFaron announces R&D Day in February 2018
11th Dec 20177:32 amRNSRecruitment completed in Traumakine INTEREST Trial
6th Dec 20176:06 pmRNSHolding(s) in Company
1st Dec 20172:55 pmRNSHoldings in Company
1st Dec 20177:01 amRNSAppointment of Chief Commercial Officer
24th Nov 201710:23 amRNSHolding(s) in Company
21st Nov 20177:00 amRNSGrant of options
20th Nov 20177:00 amRNSChange of Adviser
16th Oct 20179:00 amRNSHolding(s) in Company
13th Oct 20179:00 amRNSDirector/PDMR Shareholding
11th Oct 20172:00 pmRNSIssue of Equity & PDMR Shareholding
9th Oct 20174:30 pmRNSResult of Placing & Subscription & Issue of Equity
5th Oct 20177:00 amRNSProposed Placing and Subscription
2nd Oct 20177:00 amRNSTraumakine Receives PIM Designation from MHRA
11th Sep 20173:19 pmRNSDirectors Dealings
6th Sep 20177:00 amRNSInterim Results
4th Sep 20177:00 amRNSFDA advises Faron to proceed directly to BLA
4th Aug 20177:00 amRNSUpdate on INTEREST Phase III Study from IDMC
28th Jul 20179:34 amRNSHolding(s) in Company
10th Jul 20174:51 pmRNSHolding(s) in Company
10th Jul 20177:00 amRNSNotice of Results
16th Jun 20172:43 pmRNSDirector/PDMR Shareholding
1st Jun 20177:00 amRNSExercise of Warrants and Options
30th May 20172:06 pmRNSHoldings in Company
22nd May 201711:31 amRNSDirector/PDMR Shareholding
22nd May 20177:00 amRNSDirector/PDMR Shareholding
18th May 20179:20 amRNSDirector/PDMR Shareholding
16th May 201712:00 pmRNSResult of AGM
8th May 20174:40 pmRNSSecond Price Monitoring Extn
8th May 20174:35 pmRNSPrice Monitoring Extension
8th May 20177:00 amRNSUpdate on INTEREST Phase III Study from IDMC
27th Apr 20175:57 pmRNSExercise of Warrants
26th Apr 201712:32 pmRNSDirector's dealings
21st Apr 20175:56 pmRNSDirector/PDMR Shareholding
19th Apr 20177:00 amRNSNotice of Annual General Meeting
19th Apr 20177:00 amRNSProposed Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.